Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma.

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study ...

On Sunday, June 15, Landgren will be presenting his abstract, “A Randomized, Multi-Center Study of Carfilzomib, Lenalidomide, and Dexamethasone (KRD) With or Without Daratumumab (D) For the ...

An organizational structure helps companies assign duties and responsibilities to various staff and departments. It also helps everyone understand where they fit in to a business operation and who ...

Identifying and acting on ESG opportunities requires high-quality, complete and reliable data. Our suite of comprehensive sustainability datasets is available for scalable enterprise-wide use via ...

The bureaucracy may grow into a complex structure with multiple layers and cumbersome procedures. Bureaucracies can render an organization rigid and rule-bound. One of the key characteristics of a ...

Bona fide term structure of risk that forecasts portfolio volatility at different prediction horizons. Highest level of customization and accuracy to expose drivers of outperformance across ...

compared to Genmab and Johnson & Johnson’s anti-CD37 therapy Darzalex (daratumumab) – both given on top of Takeda’s Velcade (bortezomib) plus dexamethasone (BorDex) – when used as second ...

DREAMM-7 is pitting Blenrep against J&J's CD38 drug Darzalex (daratumumab), both in combination with Takeda's proteasome inhibitor Velcade (bortezomib) and dexamethasone, as second-line therapy ...

Save guides, add subjects and pick up where you left off with your BBC account. Multiple choice questions appear throughout both exam papers, and at both foundation tier and higher tier. Multiple ...

The lack of structural definition in nanomedicines limits therapeutic efficacy and complicates regulatory approval. Here, we emphasize that defining, designing and optimizing the structures of ...

The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.